Formerly | 10X Technologies, Inc. |
---|---|
Company type | Public |
| |
Founded | 2012 |
Founders |
|
Headquarters | Pleasanton, California, U.S. |
Key people | |
Revenue | US$618.7 million (2023) |
US$−265 million (2023) | |
US$−255 million (2023) | |
Total assets | US$965.1 million (2023) |
Total equity | US$741.0 million (2023) |
Number of employees | 1,259 (2023) |
Website | 10xgenomics |
Footnotes /references [1] [2] |
10x Genomics, Inc. is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. [2]
10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment for use in cellular biology. [3] Prior to starting the company, Saxonov was the founding architect, and director of research and development at 23andMe. [2] Ness left 10x Genomics in December 2016 [4] and in 2018, Justin McAnear, Tesla's former finance chief joined the company as CFO. [5]
In August 2018 the company announced its first acquisition, Epinomics, a biotechnology company focused on the development of new techniques for epigenetics research. [6] Four months later, 10x Genomics acquired Spatial Transcriptomics, a biotechnology company working in the field of spatial genomics. [7] In November 2018, 10x Genomics announced expansion plans including opening a manufacturing facility in Pleasanton, California in early 2019. [8]
10x Genomics announced its initial public offering on September 12, 2019, raising $390M. [9] [10] The company had revenues of $3.32 million in 2015, $27.48 million in 2016, $71.18 million in 2017, [11] $145 million in 2018, [12] and $618.7 million in 2023. [1]
Saxonov, Hindson, and Ness worked together at Quantalife prior to its acquisition by Bio-Rad in 2011 and left in 2012 to launch 10x Genomics. In 2014 an arbitration dispute was brought against the three cofounders by Bio-Rad, claiming they had breached obligations they allegedly owed to Bio-Rad after it acquired Quantalife. In 2015 an arbitrator determined that the founders of 10x Genomics had not breached their obligation to Bio-Rad when they left the company and denied its claims. [13]
In November 2018, a Delaware jury found that 10x Genomics infringed on several University of Chicago patents which were exclusively licensed to Bio-Rad. 10x Genomics were ordered to pay $24 million in damages to Bio-Rad and a 15% royalty on sales. [14] [15] 10x Genomics appealed the verdict but the decision was upheld in August 2020. [16] [17] In July 2021, Bio-Rad and 10x Genomics settled all outstanding lawsuits brought in American federal as well as international courts for an undisclosed amount and the rights for the companies to license each other's patents for single-cell analysis. [18]
BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian District, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project. It also sequences the genomes of other animals, plants and microorganisms.
Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.
George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
bioMérieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, close to Lyon. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.
CLC bio was a bioinformatics software company that developed a software suite subsequently purchased by QIAGEN.
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California, and it serves more than 155 countries. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets.
Jonathan Marc Rothberg is an American scientist and entrepreneur. He is best known for his contributions to next-generation DNA sequencing. He works and resides in Guilford, Connecticut.
Life Technologies Corporation was a biotech company founded in November 2008 through a US $6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees and owned more than 3,600 licenses and patents.
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
Anuradha Acharya is an Indian entrepreneur. She is the founder and CEO of Ocimum Bio Solutions and Mapmygenome. She was awarded Young Global Leader by the World Economic Forum in 2011.
P. Ananda Kumar is an Indian plant molecular biologist and biotechnologist.
DNAnexus is an American company that provides a cloud-based data analysis and management platform for DNA sequence data. It is based in Mountain View, California, and was founded in 2009 by Stanford University professors Serafim Batzoglou and Arend Sidow and Stanford computer scientist Andreas Sundquist.
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.
PDL BioPharma is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.
Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised five funds: Foresite Capital Fund I, II, III, IV and V.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Aclara Biosciences, Inc. was a medical technology company focused on developing applications of microfluidics for use in laboratory testing. It was publicly traded on NASDAQ under the symbol ACLA.
MGI or MGI Tech is a Chinese biotechnology company, which provides a line of products and technologies that serves the genetic sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in Shenzhen, China.
Linked-read sequencing, a type of DNA sequencing technology, uses specialized technique that tags DNA molecules with unique barcodes before fragmenting them. Unlike traditional sequencing technology, where DNA is broken into small fragments and then sequenced individually, resulting in short read lengths that has difficulties in accurately reconstructing the original DNA sequence, the unique barcodes of linked-read sequencing allows scientists to link together DNA fragments that come from the same DNA molecule. A pivotal benefit of this technology lies in the small quantities of DNA required for large genome information output, effectively combining the advantages of long-read and short-read technologies.
{{cite web}}
: CS1 maint: numeric names: authors list (link)